Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) saw unusually-strong trading volume on Tuesday . Approximately 193,313 shares were traded during mid-day trading, a decline of 3% from the previous session’s volume of 198,310 shares.The stock last traded at $3.80 and had previously closed at $3.72.

Several research analysts recently issued reports on DRNA shares. Stifel Nicolaus cut their target price on shares of Dicerna Pharmaceuticals from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, May 10th. Jefferies Group reiterated a “buy” rating and issued a $19.00 target price on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 10th. Leerink Swann reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 10th. Cowen and Company reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 10th. Finally, Zacks Investment Research upgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a research report on Thursday, May 12th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $11.85.

The stock’s 50 day moving average is $3.38 and its 200-day moving average is $4.23. The firm’s market capitalization is $76.37 million.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.09. Equities research analysts anticipate that Dicerna Pharmaceuticals Inc. will post ($3.17) EPS for the current year.

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.